|

MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative Neoplasms

RECRUITINGSponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Actively Recruiting
SponsorFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Started2025-02-17
Est. completion2044-06
Eligibility
Age16 Years+
Healthy vol.Accepted

Summary

Chronic myeloproliferative neoplasms (MPNs) are hematologic disorders of the myeloid lineage characterized by clonal proliferation of hematopoietic stem cells, high risk of thrombotic-hemorrhagic complications, and transformation into secondary acute myeloid leukemia. MPNs include: myelofibrosis, polycythemia vera, and essential thrombocythemia. The low incidence, comparable to that of rare diseases, induces the in-depth study of patients and thus the need to develop a project with databases to collect clinical, biological, and therapeutic information.

Eligibility

Age: 16 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients 16 years of age and older
* Patients diagnosed with polycythemia vera, essential thrombocythemia, prefibrotic and overt primary myelofibrosis, secondary myelofibrosis (Arber et al, Blood 2022 or earlier but reclassified classifications)

Exclusion Criteria:

* Patients with diagnosis other than polycythemia vera, essential thrombocythemia, prefibrotic and overt primary myelofibrosis, secondary myelofibrosis
* Follow up of less than 6 months

Conditions4

CancerEssential ThrombocythaemiaMyelofibrosis (MF)Polycythemia Vera

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.